Panelists:
+ Chantell Sell, PharmD, National Pharmacy Clinical Lead, Willis Towers Watson
+ Sami Inkinen, MSc, MBA, CEO and Co-Founder, Virta Health
+ Hassan Azar, JD, MBA, MPH, MHA, MA, VP Global Benefits, Jones Lang LaSalle

Obesity rates continue to soar, but earlier this month we were met with intriguing news. On June 4th, the FDA approved a new weight-loss drug in which the outcomes which were described as “breakthrough” and “game-changing” Patients on average lost 33.7 pounds after 68 weeks, more than 1.5x higher than the next best obesity drug. Experts predict the record-breaking efficacy rates could unleash the obesity drug market, which has historically lingered at a low of less than 1% penetration rate.

Despite what looks like a promising turn of events at the surface, there is growing concern that we’re at a tipping point for a healthcare cost crisis. With an estimated list price per patient of $15,600 this newly approved GLP-1 could take a huge hit on employers and payers who are already struggling to control growing medication and healthcare costs.

Learn more about Virta Health at https://www.virtahealth.com

Follow us at:
  / virtahealth  
  / virtahealth  
  / virta-health